Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 209

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 209
---
 following the initial injection (2.0%) and repeat injection (0.7%). Otherwise, TEAEs occurring ≥2% of subjects were low and balanced between SP-102 and placebo. TEAEs occurring with an incidence ≥2% remained low following the repeat injection. |

| • |     | There were no meaningful differences observed in physical examinations, vital signs, or laboratory parameters between treatment groups. |

The data from the primary endpoint analyses is graphically presented below. Summary tables are also provided for primary and secondary endpoints. Mean Change From Baseline in NPRS Average Pain Score (Standard Error) in the Affected Leg (ITT Population) SP-102 vs Placebo Weeks 1,2,3,4: p = 0.002, 0.005, 0.003, 0.003. Overall treatment Effect (Mean SP-102 vs Placebo difference): Diff = -0.52, SE= 0.163, p =0.002. Error Bars: 95% Confidence Limits. Primary and Secondary Outcomes: NPRS Average Leg Pain In Affected Leg, ODI Total Score, Mean Daily NPRS (worst, current, and lower back), PainDetect, BPI-SF (Change from Baseline to Four Weeks; ITT Population)

|                                                                   |     | SP-102           
 N=202            |     | Placebo        
 N=199          |     | LSM (SE)      |     | 95% CI       |     | P-value |
| Endpoint                                                          |     | Mean Change      
 from Baseline(1) |     | Mean Change    
 from Baseline  |     |               |     |              |     |         |
| NPRS Average Pain Score in the Affected Leg (primary endpoint)(2) |     | -1.81 (1.896)    |     | -1.29 (1.814)  |     | -0.55 (0.187) |     | -0.92, -0.18 |     |   0.003 |
| ODI total score (key secondary endpoint)(3)                       |     | -8.88 (14.684)   |     | -5.48 (13.083) |     | -3.38 (1.388) |     | -6.11, -0.65 |     |   0.015 |
| Worst pain in affected leg at Week Four(2)                        |     |